Advertisement

Effects of Canrenone on Na+, K+ ATPase Activity, Arterial Pressure and Plasma Potassium Concentration in Uremic Hemodialyzed Patients

  • F. Quarello
  • R. Boero
  • C. Guarena
  • C. Rosati
  • G. Beltrame
  • P. Colombo
  • I. M. Berto
  • M. Aimino
  • M. Formica
  • G. Piccoli
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)

Abstract

Canrenone is the main active metabolite1 of the diuretic and antihypertensive drugs spironolactone and canrenoate-K, and competes with aldosterone for a common cytosolic receptor in distal and collecting tubules of the nephron.2 In addition it has recently been demonstrated that canrenone in vitro may directly interfere with ouabain-sensitive Na+,K+ pump (Na+,K+ adenosine triphosphatase), acting as a partial agonist at the digitalis receptor site. 3,4 Moreover Garay et al.4 showed that canrenone is able to restimulate in vitro the Na+,K+ pump of human red blood cells (RBC) blocked by high concentrations of ouabain.

Keywords

Pump Activity Uremic Patient Adenosine Triphosphatase Essential Hypertensive Patient Erythrocyte Sodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    W. Sadéé M. Dagcioglu, and R. J. Schroder, Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans, Pharmacol. Exp. Ther. 185: 686–695 (1973).Google Scholar
  2. 2.
    D. Marver and J. P. Kokko, Renal target sites and the mechanism of action of aldosterone. Min. Electrolyte Metab. 9: 1–18 (1983).Google Scholar
  3. 3.
    P. Finotti and P. Palatini, Canrenone as a partial agonist at the digitalis receptor site of sodium potassium activated adenosine triphosphatase, J. Pharmacol. Exp. Ther. 217: 784–790 (1981).PubMedGoogle Scholar
  4. 4.
    R. P. Garay, J. Diez, C. Nazaret, G. Dagher, and J. P. Abitbol, The interaction of canrenone with the Na+,K+ pump in human red blood cells, Naunyn-Schmiedeberg’s Arch. Pharmacol. 329: 311–315 (1985).CrossRefGoogle Scholar
  5. 5.
    L. G. Welt, G. R. Sachs, J. J. Macmanus, An ion transport defect in erythrocytes from uremic patients. Trans. Assoc. Am. Phys. 77: 169–181 (1964).PubMedGoogle Scholar
  6. 6.
    L. G. Welt, E. K. M. Smith, M. J. Dunn, A. Szerwinski, H. Proctor, C. Cole, J. W. Balfe and H. J. Gitelman, Membrane transport defect: the sick cell. Trans, Assoc, Am, Phys, 30: 217–226 (1967).Google Scholar
  7. 7.
    A. P. Quintanilla, Alteration of Na,K pump in the uremic state. Int. J. Artif. Organs 10: 337–442 (1988).Google Scholar
  8. 8.
    H. Izumo, S. Izumo, M. DeLuise and J. Flier, Erythrocyte pump in uremia. Acute correction of transport defect by hemodialysis, J. Clin. Invest, 74: 581–588 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    F. Quarello, R. Boero, C. Guarena, C. Rosati, M.C. Deabate, T. Fidelio and G. Piccoli, Red blood cell Na+,K+ pump activity in patients on hemofiltration. Blood Purif. 2: 130–134 (1984).CrossRefGoogle Scholar
  10. 10.
    C. H. Cole, J. W. Balfe and C. G. Welt, Induction of an ouabain sensitive ATPase defect by uremic plasma. Trans. Assoc. Am. Phys. 81: 213–221 (1968).PubMedGoogle Scholar
  11. 11.
    H. J. Kramer, J. Pennig, D. Klingmüller, J. Kipnowski, K. Glänzer and R. Düsing, Digoxin-like immunoreacting substance(s) in the serum of patients with chronic uremia. Nephron 40: 297–302 (1985).PubMedCrossRefGoogle Scholar
  12. 13.
    J. H. Acosta, Hypertension in chronic renal failure. Kidney Int. 22: 702–712 (1982).CrossRefGoogle Scholar
  13. 14.
    M. P. Blaustein, Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am. J. Physiol. 232: C165-C173 (1977).PubMedGoogle Scholar
  14. 15.
    J. Fernandez, J. R. Oster and G. O. Perez, Impaired extrarenal disposal of an acute oral potassium load in patients with end stage renal disease on chronic hemodialysis. Min. Electrolyte Metail. 12: 125–129 (1986).Google Scholar
  15. 16.
    V. Buckalew and K. Gruber, Natiuretic hormone, in: “The Kidney in Liver disease”, M. Epstein, ed., Elsevier Biomedical, New York (1983), p. 479–499.Google Scholar
  16. 17.
    J. M. Krzezinsky and G. Rorive, (letter), N. Engl. J. Med. 309: 987–988 (1983).CrossRefGoogle Scholar
  17. 18.
    F. Quarello, R. Boero, C. Guarena, C. Rosati, G. Giraudo, F. Giacchino and G. Piccoli, Acute effects of hemodialysis on erythrocyte sodium fluxes in uremic patients. Nephron 41: 22–25 (1985).PubMedCrossRefGoogle Scholar
  18. 19.
    G. Deray, M. G. Pernollet, M. A. Devynck, J. Zingraff, A. Touam, J. Rosenfeld and P. Meyer, Plasma digitalis-like activity in essential hypertension or end-stage renal disease. Hypertension 8: 632–638 (1986).PubMedCrossRefGoogle Scholar
  19. 20.
    R. Boero, F. Quarello, C. Guarena, C. Rosati and G. Piccoli, Effects of an intravenous saline load on erythrocyte sodium transport in normal human subjects, Clin. Sci. 69: 709–712 (1985).PubMedGoogle Scholar
  20. 21.
    F. Quarello, R. Boero, C. Guarena, M. C. Deabate, M. C. Forneris, C. Rosati, B. Rolando and G. Piccoli, II canrenone previene 1’inibizione della Na+,K+ pompa indotta dall’ espansione del volume extracellulare, ia: “Nefrologia Dialisi Trapianto”, C. Giordano and N. DeSanto, eds., Wichtig, Milano (1986), p. 431–434.Google Scholar
  21. 22.
    R. Boero, C. Guarena, M. C. Deabate, B. Rolando, C. Rosati, F. Quarello and G. Piccoli, Erythrocyte Na+,K+ pump inhibition following saline infusion in essential hypertensive subjects: effects of canrenone administration. Int. J. Cardiology (in press).Google Scholar
  22. 23.
    G. Pati, E. Niutta, M. G. Tripodi, C. Barlassina, D. Cusi and G. Bianchi, Inibizione dell’azione delle sostanze endogene ad attivitè ouabaino-simile da parte del canrenoato di K nell’ ipertensione arteriosa essenziale, in: “Atti XXVI Congresso Nazionale Societa Italiana di Nefrologia”, F. Mastrangelo, S. Rizzelli, V. De Blasi, L. Alfonso and D. Brancaccio, eds. Wichtig, Milano (1985), p. 247–250.Google Scholar
  23. 24.
    H. E. de Wardener and G. A. MacGregor, The natriuretic hormone and essential hypertension. Lancet 26: 1450–1454 (1982).CrossRefGoogle Scholar
  24. 25.
    M. De Mendonca, M. L. Grichois, M. G. Pernollet, B. Thorman, P. Meyer, M. A. Devynck and R. Garay, Hypotensive action of canrenone in a model of hypertension where ouabain-like factors are present, J. Hypertension 3 (suppl. 3): 73–75 (1985).Google Scholar
  25. 26.
    M. L. Grichois, M. De Mendonca, I. Wauquier, M. G. Pernollet, B. Thorman, M. A. Devynck, P. Meyer and R. P. Garay, La canrénone: un antihypertenseur efficace dans le modèle expérimental d’hypertension Où le transport actif du sodium est diminué. Arch. Mai. Coeur 6: 875–878 (1986).Google Scholar
  26. 27.
    J. Brod, J. Shaeffer, H. Hengtenberg and T. Kleinschmidt, Investig ations on the Na+,K+ pump in erythrocytes of patients with renal hypertension, Clin. Sci. 66: 351–355 (1984).PubMedGoogle Scholar
  27. 28.
    R. Boero, C. Guarena, I. M. Berto, M. C. Deabate, C. Rosati, F. Quarello and G. Piccoli, Erythrocyte pump activity and arterial hypertension in uremic dialyzed patients (submitted).Google Scholar
  28. 29.
    P. Salvati, F. Vaghi, M. Colombo and G. Bianchi, The interaction of canrenone with the Na,K pump in isolated rabbit renal arteries, in: “Abs. Xth Int. Congr. Nephrol.”, London (1987), p. 300.Google Scholar
  29. 30.
    S. Laurent, P. Hannaert, X. Girard, M. Safar and R. P. Garay. Chronic treatment with canrenone in essential hypertensive patients potentiates the acute pressor effect of ouabain, J. Hypertension 5: S173-S175 (1987).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • F. Quarello
    • 1
    • 2
  • R. Boero
    • 1
    • 2
  • C. Guarena
    • 1
    • 2
  • C. Rosati
    • 1
    • 2
  • G. Beltrame
    • 1
    • 2
  • P. Colombo
    • 1
    • 2
  • I. M. Berto
    • 1
    • 2
  • M. Aimino
    • 1
    • 2
  • M. Formica
    • 1
    • 2
  • G. Piccoli
    • 1
    • 2
  1. 1.Institute of NephrologyUniversity of TorinoTorinoItaly
  2. 2.Dialysis UnitNuova Astanteria Martini HospitalTorinoItaly

Personalised recommendations